SCLC
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 11/08/2022)
Non-metastatic stage
KEYLINK-013 (MSD)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Metastatic stage
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Metastatic stage
1st line
Currently no open trials
2nd line
Currently no open trials
3rd line
Currently no open trials
2nd line
Currently no open trials
3rd line
Currently no open trials